IgA Vasculitis in the Setting of Biologic Therapy for Psoriasis and Recurrent Cutaneous Methicillin-Resistant Staphylococcus aureus Colonization

Cutis. 2022 Oct;110(4):E4-E10. doi: 10.12788/cutis.0636.

Abstract

IgA vasculitis is a form of cutaneous small-vessel leukocytoclastic vasculitis (LCV) that has various triggers, including anti-tumor necrosis factor (TNF) α therapy. As the use of more targeted biologic therapies such as the IL-17 inhibitor secukinumab increases, so do reports of associated adverse events. Herein, we describe an uncommon case of IgA vasculitis in a man undergoing biologic therapy with adalimumab and secukinumab for psoriasis with recurrent cutaneous methicillin-resistant Staphylococcus aureus (MRSA) colonization. A review of the current literature also is provided.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adalimumab / therapeutic use
  • Biological Therapy
  • Humans
  • IgA Vasculitis*
  • Male
  • Methicillin-Resistant Staphylococcus aureus*
  • Psoriasis* / drug therapy
  • Vasculitis, Leukocytoclastic, Cutaneous* / drug therapy

Substances

  • Adalimumab